ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX

EHA Library, Vikas Bhuria, 385454

EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING

EHA Library, Subbaiah Chary Nimmagadda, 385455

TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)

EHA Library, sergey lepkov, 385546

CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY

EHA Library, Mazyar Shadman, 385547

A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)

EHA Library, Daniel Hodson, 385548

A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY

EHA Library, WeiLi Zhao, 385549

PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA.

EHA Library, Ana Jiménez Ubieto, 385550

A PROSPECTIVE TRIAL OF A NOVEL RECOMBINANT HUMANIZEDANTI-INTERLEUKIN-6 RECEPTOR MONOCLONAL ANTIBODY INJECTION(VDJ001) IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: THE PRELIMINARY RESULTS

EHA Library, Lu Zhang, 385551

IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY

EHA Library, Rohan Shotton, 385552

OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA

EHA Library, Tomasz Wróbel, 385553

THE PROGNOSTIC ROLE OF DEPTH OF RESPONSE DEPENDS ON THE TIME OF ASSESSMENT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY IN PATIENTS WITH SYMPTOMATIC WALDENSTROM MACROGOBULINEMIA (WM).

EHA Library, Lydia Montes, 385554

NEUROLOGIC INVOLVEMENT IN ADULTS WITH ROSAI-DORFMAN DISEASE: CLINICAL PRESENTATION AND OUTCOMES

EHA Library, Aldo Acosta Medina, 385555

CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.

EHA Library, Kei Hirano, 385556

ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Andrew J. Davies, 385557

EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

EHA Library, Lydia Scarfò, 385558

EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.

EHA Library, Erika Morsia, 385559

REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)

EHA Library, Bijal D. Shah, 385560

WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (≥75-YEAR-OLD): DESCRIPTION OF CLINICAL  FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN  ACADEMIC CENTER

EHA Library, Nicolò Danesin, 385561

PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY

EHA Library, Nalin Payakachat, 385562

COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Catherine Thieblemont, 385563

HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA (FL)

EHA Library, Carmelo Carlo-Stella, 385564

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

EHA Library, Jan Walewski, 385565

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

EHA Library, Michael Roost Clausen, 385566

GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

EHA Library, Adrian Minson, 385567

LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Wojciech Jurczak, 385568

CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY

EHA Library, Zhi-Ming Li, 385569

NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.

EHA Library, Li Wang, 385570

POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?

EHA Library, Theodoros Vassilakopoulos, 385571

A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA

EHA Library, Stefan Habringer, 385572

EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY

EHA Library, Marie-Helene DELFAU-LARUE, 385573

DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY

EHA Library, Eric Jacobsen, 385574

DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

EHA Library, Javier Munoz, 385575

PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

EHA Library, Paolo Strati, 385576

FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, Emma Verner, 385577

EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY

EHA Library, Elise R.A. Pennings, 385578

FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032

EHA Library, Swaminathan Iyer, 385580

SERUM TRIGLYCERIDE AND APOLIPOPROTEIN A1 AS BIOMARKERS FOR EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (ENKTL): A MULTICENTER STUDY

EHA Library, Qingqing Cai, 385581

LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Paolo F Caimi, 385582

CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL

EHA Library, Jinhua Liang, 385583

BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABATAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

EHA Library, Nirav Shah, 385584

EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY

EHA Library, Sabrina Pierre, 385585

FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Huilai Zhang, 385586

COMBINED METABOLIC HETEROGENEITY AND TOTAL LESION GLYCOLYSIS FROM PET-CT IMPROVES THE PROGNOSTIC STRATIFICATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

EHA Library, Daisuke Ikeda, 385587

COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS

EHA Library, Carolien Maas, 385589

COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL

EHA Library, Hui-qiang Huang, 385590

ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS

EHA Library, Jake Shortt, 385591

AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY

EHA Library, Won-Seog Kim, 385592

ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, bobin chen, 385593

PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

EHA Library, Haorui Shen, 385595

TRANSFUSION NEEDS AFTER CD19 CAR T-CELLS FOR LARGE B-CELL LYMPHOMA: PREDICTIVE FACTORS AND IMPACT ON OUTCOME. A DESCAR-T STUDY.

EHA Library, Samuel Vic, 385596

FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL

EHA Library, Josep Maria Ribera, 385597

MULTI-SITE PRE-THERAPEUTIC BIOPSIES REVEALS GENETIC HETEROGENEITY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Ditte Stampe Hersby, 385598

COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS

EHA Library, Allison Rosenthal, 385599

A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA

EHA Library, Hui Zhou, 385600

BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

EHA Library, Gloria Iacoboni, 385601

DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Allison Bock, 385602

UTILITY OF THE FRAILTY SCORE FOR PREDICTING PROGNOSIS AND INDIVIDUALIZING TREATMENT INTENSITY IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yu Yagi, 385603

EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON

EHA Library, Gilles Salles, 385604

MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Jinhua Liang, 385605

IN THE ABSENCE OF SYMPTOMS OR CEREBROSPINAL FLUID INVOLVEMENT, MRI STAGING OF THE CENTRAL NERVOUS SYSTEM (CNS) IN PATIENTS WITH SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA RARELY DETECTS DISEASE

EHA Library, Manu Juneja, 385606

PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS

EHA Library, Ja Min Byun, 385607

REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT OUTCOMES OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) BY LINE OF THERAPY (LOT)

EHA Library, Christina Zettler, 385608

INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP

EHA Library, Diana Al-Sarayfi, 385609

METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA

EHA Library, Li-Jie Xing, 385610

THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.

EHA Library, Francien Huisman, 385611

FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA

EHA Library, Hesong Zou, 385612

ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Ling Wang, 385613

PEGARSPARGASE AND SINTILIMAB FOR NEWLY DIAGNOSED, ADVANCED STAGE NATURAL KILLER T-CELL LYMPHOMA, NASAL TYPE: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.

EHA Library, Jie Xiong, 385614

PRELIMINARY FINDINGS OF A PHASE Ⅱ STUDY OF CHEMO-FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH-DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA

EHA Library, Yan Zhang, 385615

BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN

EHA Library, David Sibon, 385616

TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB)，A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETING MYC DEGRADATION

EHA Library, Sung-Soo Yoon, 385617

DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL

EHA Library, Peihao Zheng, 385618

COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY

EHA Library, Alex Mutebi, 385619

CAR-T THERAPY IS EFFECTIVE AND SAFE IN TREATING RELAPSED/REFRACTORY LYMPHOMA WITH MALIGNANT SEROUS CAVITY EFFUSION

EHA Library, Lefu Huang, 385620

CNS RELAPSE OF DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL PRESENTATION, OUTCOME AND ROLE OF UPFRONT PROPHYLAXIS: A 10-YEAR SINGLE CENTER EXPERIENCE.

EHA Library, Corrado Benevolo Savelli, 385621

ARTIFICIAL INTELLIGENCE FOR PROGNOSIS PREDICTION OF NATURAL KILLER/T-CELL LYMPHOMA BASED ON MAGNETIC RESONANCE IMAGING

EHA Library, Qingqing Cai, 385622

EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA

EHA Library, Fan Yang, 385623

PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY

EHA Library, Zhi-Ming Li, 385624

THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES

EHA Library, Ivan Civettini, 385625

CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Tongsheng Wang, 385626

ROUTINE CLINICAL FOLLOW-UP FOR RELAPSE DETECTION IN PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FIRST-LINE TREATMENT – DOES NOT MEET THE AIMS. A RETROSPECTIVE DANISH MULTICENTER STUDY

EHA Library, Therese Lassen, 385627

THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP

EHA Library, Theodoros Vassilakopoulos, 385628

PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE

EHA Library, Liudmila Fedorova, 385629

BURKITT INTERNATIONAL PROGNOSTIC INDEX EVALUATED IN PATIENTS TREATED WITH R-GMALL PROTOCOL

EHA Library, Giuliana Rizzuto, 385630

REAL-LIFE TREATMENT APPROACHES AND THERAPY RESULTS IN THE PATIENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA: POLISH-UKRAINIAN EXPERIENCE

EHA Library, Kateryna Filonenko, 385631

A PROSPECTIVE STUDY OF TCR MEASURABLE RESIDUAL DISEASE IN PERIPHERAL T-CELL LYMPHOMA

EHA Library, Austin Jacobsen, 385632

CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS AND AT RELAPSE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE “RETE EMATOLOGICA VENETA” (T-REV PROJECT).

EHA Library, Marcello Riva, 385633

INTERIM DELTASUVMAX CAN IDENTIFY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA WITH A HIGH RISK OF PRIMARY REFRACTORY DISEASE CANDIDATES FOR EARLY CART COLLECTION

EHA Library, Carolina Feres, 385634

A PROSPECTIVE SINGLE-CENTER PHASE 2 STUDY OF ZANUBRUTINIB PLUS R-CHOP IN TREAT-NAÏVE INTRAVASCULAR LARGE B CELL LYMPHOMA

EHA Library, Yan Zhang, 385635

RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.

EHA Library, Caixia Li, 385636

SAFETY AND EFFICACY OF ANTICD20-CD3 BISPECIFIC T-CELL ENGAGING ANTIBODIES IN THE MANAGEMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW OF CLINICAL TRIALS

EHA Library, Mansoor Rahman, 385637

DYNAMIC CHANGES IN CIRCULATING EBV-DNA LOAD DURING TREATMENT HAVE PROGNOSTIC VALUES IN EBV+ DLBCL-NOS: A CHINESE COHORT STUDY

EHA Library, Jinhua Liang, 385638

ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY

EHA Library, Ronakrit Thanhakun, 385639

EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA.

EHA Library, Zhi-Ming Li, 385640

A NOVEL PROGNOSTIC MODEL OF DLBCL PATIENTS BASED ON CUPROPTOSIS RELATED GENES

EHA Library, Fu Li, 385641

ANTI-PD-1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R-CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A PROSPENTIVE PHASE II STUDY

EHA Library, Shujuan Wen, 385642

POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA-BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL-INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY

EHA Library, Briony Shaw, 385643

PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL 18F-FDG PET/CT DURING THE TREATMENT OF ANTHRACYCLINE-CONTAINING FRONTLINE CHEMOTHERAPY IN PERIPHERAL T CELL LYMPHOMAS

EHA Library, Deok-Hwan Yang, 385644

A PROSPECTIVE STUDY OF  TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.

EHA Library, Yuelu Guo, 385645

PERSISTENCE WITH ORAL THERAPY AS REFLECTION OF ACTUAL COMPLIANCE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A NATIONAL PRESCRIBED DRUG AND PATIENT REGISTER STUDY FROM SWEDEN

EHA Library, Nasim BAHAR, 388014